- 1 Antibiotic utilisation and the impact of antimicrobial resistance action plan on
- 2 prescribing among older adults in New Zealand between 2005 and 2019
- **Authors** 3
- Tichawona Chinzowu (MSc), Department of Life Sciences, University of Bath, United 4
- 5 Kingdom
- 6 Te-yuan Chyou (PhD), Department of Biochemistry, University of Otago, Dunedin,
- 7 New Zealand
- Sandipan Roy (PhD), Department of Mathematical Sciences, University of Bath. 8
- 9 Hamish Jamieson (PhD), Associate Professor and Geriatrician, University of Otago
- Christchurch, Department of Medicine; Burwood Hospital, Christchurch, New 10
- 11 Zealand
- Prasad S Nishtala (PhD), Department of Life Sciences, University of Bath, United 12
- Kingdom 13
- 14 and

18

- Centre for Therapeutic Innovation, University of Bath, United Kingdom 15
- Running title: Antibiotic utilisation patterns 17
- 19 Address correspondence to:
- 20 Tichawona Chinzowu, Department of Pharmacy and Pharmacology, University of
- Bath, Bath 21
- BA2 7AY, United Kingdom 22
- Email: tc888@bath.ac.uk 23
- Word count: 3114 (excluding references) 25 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Abstract** 

26

27 28

30

31

32

33

37

38

39

40

41

42

43

44

45

46

48

49

50

51

52

53

54

55

29 Purpose: The objectives of this study were to examine the overall utilisation of

systematic antibiotics and the impact of the launch of the antimicrobial resistance

action plan in older adults (65 years or more) living in New Zealand between 2005 and

2019, using data from a national database (Pharmaceutical collections), stratified by

antibiotic class, patient age, and sex.

Methods: Population-level systemic antibiotic dispensing data for older adults in New 34

Zealand was analysed using repeated cross-sectional analysis between 01/01/2005 35

and 31/12/2019. Data were extracted on the prescribed systemic antibiotics using a 36

unique identifier for each case. Antibiotic utilisation was measured in DDD/TOPD

values. In addition, an interrupted time series (ITS) analysis using the autoregressive

integrated moving average (ARIMA) models was performed to determine the impact

of the antimicrobial resistance action plan.

Results: Most of the antibiotic classes included in this study showed a significant

overall decrease in utilisation ranging from 38.64% for sulphonamides to 80.64% for

fluoroguinolones compared to 2005. Systemic antibiotic utilisation decreased by

49.6% from the predicted usage between January 2018 and December 2019 following

the launch of the antimicrobial resistance action plan. ARIMA model supported the

reduction in utilisation with a step change of -0.2206 and slope change of -0.0029.

47 Conclusions: The ITS analysis has demonstrated that the intervention may have

hugely impacted the antibiotic utilisation rate among older adults. Further studies are

required to determine whether the reduced consumption rates of antibiotics are

associated with reduced rates of antibiotic-associated adverse drug events such as

acute kidney injury and haematological abnormalities.

**Keywords:** antimicrobial, consumption, prescribing, defined daily dose, elderly, time

series, ARIMA model

#### Introduction

56 57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Inappropriate prescribing of antibiotics is an important driver of the rising global antibiotic resistance and a direct threat to the safety of patients due to the increased risk of adverse drug events such as acute kidney injury, haematologic, gastrointestinal, dermatologic and hepatobiliary abnormalities [1-3]. Outpatient and community utilisation of antibiotics is on the rise, with older adults (>65 years of age) receiving the highest prescribing rate compared to any other age group [4]. In the United States, older adults are one and half times more likely to receive antibiotics than younger adults in a year [5, 6]. In over 46% of visits involving non-bacterial respiratory tract infections, adults ≥65 receive unnecessary antibiotics, most of which are broadspectrum agents [7, 8]. This increased rate of inappropriate prescribing raises concerns for older adults who are already at increased risk for serious adverse drug events due to age-related physiologic changes, comorbidities, and polypharmacy [9]. Antibiotics, as a class, are the third commonest cause of adverse drug events among older adults. Nearly 15% of all emergency department visits for antibiotic-associated adverse drug events occur in older adults [10].

Specific antibiotic classes pose increased safety risks for older adults. For example, fluoroquinolones have been reported to put older adults at an elevated risk of serious adverse events, including tendon rupture, blood sugar disturbances, peripheral neuropathy, delirium and aortic dissection [11]. Macrolides, commonly prescribed to older adults, were associated with an elevated risk of cardiac arrhythmia and death, particularly in males [12]. Cotrimoxazole requires close monitoring in older adults due to the risk of pre-existing renal insufficiency necessitating dose adjustment [1].

There was a significant decrease in annual antibiotic usage between 2014 and 2018 among most countries in the world Health Organisation (WHO) Europe region, including the United Kingdom, Germany, and Finland [13]. In their study, Andersson et al. [14] showed consistently higher antibiotic usage in Australia compared to Sweden. In New Zealand, systemic antibiotic consumption increased from 17.31 to 25.79 DDD per 1000 per day between 2006 and 2014 [15]. In another New Zealand study, systemic antibiotics' consumption increased by 2% between 2010 and 2015 among older adults [16].

For population-level health interventions, the interrupted time series (ITS) analysis is a valuable tool for evaluating their effectiveness, provided they were implemented at a well-defined time point [17]. Segmented regression is a commonly used approach for ITS analysis. However, it is not adequate in autocorrelation and seasonality [18]. An alternative method, the ARIMA model, can accommodate both seasonality and autocorrelation [18].

Few studies describe the utilisation of systematic antibiotics at the population level, specifically among older adults in New Zealand, and how the utilisation rates respond to interventions primarily aimed at mitigating the development of antimicrobial resistance. Therefore, the objectives of this study were to examine the overall utilisation of systematic antibiotics and the impact of the launch of the antimicrobial resistance action plan in older adults (65 years or more) living in New Zealand between 2005 and 2019, using data from a national database (Pharms), stratified by the rapeutic class, age, and sex, based on the World Health Organisation Collaborating Centre for Drug Statistics Methodology (WHOCC) Anatomical Therapeutic Chemical (ATC) classification.

#### **Methods**

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105 106

107

108

109

110

111

112

113

114

115

116

117

118

119

#### Study design

Population-level systemic antibiotic dispensing data for older adults in New Zealand was analysed using repeated cross-sectional analysis between 1st January 2005 and 31st December 2019. Data were extracted on the prescribed systemic antibiotics using a unique identifier for each case and analysed for utilisation in DDDs according to patients' antibiotic class, age, and sex. This study included dispensing claims data for all funded antibiotics by community pharmacies.

#### Data source

From 1st January 2005 to 31st December 2019, de-identified individual dispensing claims data for older adults (65 years and above) were extracted from the Pharmaceutical Collections [19, 20]. Pharmaceutical collections are the New Zealand Ministry of Health's national dispensing claims database which captures subsidised prescriptions dispensed by community pharmacies [21]. Antibiotics were categorised

using the ATC developed by WHOCC. The following antibiotic classes were included 120

in this study: penicillins (J01C), macrolides (J01F), cephalosporins (J01D), 121

tetracyclines (J01A), sulphonamides (J01E), fluoroguinolones 122 (J01M),

aminoglycosides (J01G), and 'other antibiotics' (J01X) [22]. In addition, metronidazole,

nitrofurantoin, and vancomycin were classified as 'Other antibiotics' (J01X).

#### Data analysis

123

124

125

- DDDs were computed for each antibiotic dispensed to an individual yearly and 127
- normalised by age group, antibiotic class, and sex at a population level. In this study, 128
- the DDD per 1000 older people per day (TOPD) measures the proportion of people 129
- being treated with a daily dose of antibiotic dispensed within a defined study area per 130
- 1000 older people per day. Antibiotic utilisation by class, sex and age were also 131
- measured in DDD/TOPD values. The DDDs were computed for each antibiotic utilised 132
- by an individual yearly, per annual population size of New Zealand between 2005 and 133
- 2019. The R statistical software (version 4.2.0) was used in all analyses [23]. 134
- Interrupted time series analysis 135
- Using the R statistical software (version 4.2.0), we determined the effect of introducing 136
- 137 the antimicrobial resistance action plan in January 2018 in New Zealand on antibiotic
- prescribing and utilisation rates among older adults. We performed ITS analysis using 138
- the ARIMA model [18] on monthly antibiotic utilisation rates to understand the effect 139
- of the implemented national antimicrobial resistance action plan [18]. Monthly 140
- DDD/TOPDs were computed above for the study period and population. The pre-141
- intervention period was from January 2005 to December 2017, and the post-142
- intervention period was from January 2018 to December 2019. 143
- Firstly, the time series data was plotted to understand any patterns, including trends 144
- and seasonal variations. Then, the forecast R package [23] was used to determine 145
- p/P and q/Q parameters. Next, stationarity was induced using the first-order difference 146
- where d = 1 and D = 1 for trend and seasonal differences, respectively. Next, we 147
- plotted the autocorrelation and partial autocorrelation functions (ACF/PACF) of 148
- stationarity data to view and confirm the ARIMA orders from the automated algorithms. 149
- 150 Finally, the Ljung-Box test [18] was used to test whether residuals for the model were
- white noise or not. 151

Counterfactual values for the post-intervention period were determined and plotted together with observed values to visualise the impact of the intervention on the antimicrobial utilisation rate among older adults.

#### Results

152

153

154

155

156 157

158

159

160

161

162

163

164

165

166

#### Overall trend

Table 1 shows the percentage change in the utilisation of funded systemic antibiotics among older adults between 2005 and 2019 in New Zealand. Overall systemic antibiotic utilisation decreased by 56.28% between 2005 and 2019, averaging an annual decrease of 4.02% (Table 1). However, utilisation remained high from 2005 to 2017, declining between 2018 and 2019 (Figure 1) following the implementation of the New Zealand Antimicrobial Resistance Action Plan [24].

**Table 1**: Utilization of antibacterial agents (in defined daily dose per 1000 older people per day [DDD/TOPD] values) between 2005 and 2019.

Antibacterial class	Antibacterial name	Subsidized	WHO ATC classification	2005 DDD/TOPD	2019 DDD/TOPD	Change (%)
Aminoglycosides	Gentamicin sulphate	Partly	J01GB03	0.0023	0.0015	-31.9
Subtotal	Tobramycin <sup>2</sup>	Partly	J01GB01	0.0038 <b>0.0059</b>	0.0004 <b>0.0019</b>	-88.8 <b>-68.0</b>
Cephalosporins	Cefuroxime axetil3	Partly	J01DC02	0.0092	0.0081	-12.0
	Cefaclor monohydrate	Yes	J01DC04	1.2259	0.7492	-38.9
	Ceftriaxone <sub>4</sub>	Partly	J01DD04	<0.0001	0.0010	5215.2
	Cefalexin	Yes	J01DB01	0.0863	0.6281	627.8
	Cefazolin	Yes	J01DB01	0.0031	0.0016	-50.0
Subtotal				1.3249	1.3879	4.8
Fluoroquinolones	Norfloxacin₅	Partly	J01MA06	1.0518	0.0381	-96.4
	Ciprofloxacin	Yes	J01MA02	0.9586	0.3490	-63.6
Subtotal				2.0104	0.3872	-80.7
Macrolides	Azithromycin	Yes	J01FA10	0.0017	0.1147	6640.7
	Clindamycin	Yes	J01FF01	0.9075	0.7210	-20.6

	Roxithromycin	Yes	J01FA06	1.8771	0.6620	-64.7
	Clarithromycin	Partly	J01FA09	0.0662	0.0119	-82.1
	Erythromycin ethyl succinate	Yes	J01FA01	1.8436	0.4295	-76.7
	Erythromycin stearate	Yes	J01FA01	0.1696	0.0131	-92.3
	Erythromycin (as lactobionate)	Yes	J01FA01	0.0001	<0.0001	-48.1
Subtotal	, ,			4.8659	1.952243	-59.9
Other antibiotics	Metronidazole	Yes	J01XD01	0.9267	0.3647	-60.7
	Nitrofurantoin	Yes	J01XE01	1.2779	1.0226	-20.0
	Vancomycin <sup>,</sup>	Partly	J01XA01	0.0029	0.0033	13.8
Subtotal				2.2075	1.3906	-37.0
Penicillins	Amoxicillin- clavulanic acid	Yes	J01CR02	4.9023	1.0866	-77.8
	Amoxicillin	Yes	J01CA04	2.5529	1.2829	-49.8
	Benzathine benzylpenicillin	Yes	J01CE08	0.1901	0.0071	-96.3
	Dicloxacillin	No	J01CF01	0.0656	0	NA
	Penicillin G	Yes	J01CE09	0.0017	0.0001	-91.2
	Penicillin V	Yes	J01CE02	0.2428	0.0955	-60.7
	Flucloxacillin	Yes	J01CF05	2.0635	1.3127	-36.4
Subtotal				10.0188	3.7848	-62.2
Sulphonamides	Co- trimoxazole	Yes	J01EE01	0.7813	0.4340	-44.5
	Trimethoprim	Yes	J01EA01	1.7506	1.1192	-36.1
Subtotal				2.5319	1.5533	-38.7
Tetracyclines Subtotal	Doxycycline	Yes	J01AA02	5.6786	2.0642	-63.7
	•			5.6786	2.0642	-63.7
Total (all antibact	28.6440	12.5221	-56.3			

Notes:

167

168

169

170

171

172

173

- 1. Gentamicin sulphate subsidised only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.
- 2. Tobramycin subsidised only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.
- 3. Cefuroxime axetil subsidised only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.

4. Ceftriaxone subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningococcal disease, and the prescription or PSO is endorsed accordingly

- 5. Norfloxacillin subsidised only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.
- 6. Clarithromycin subsidized for Helicobacter pylori infections only.
- 7. Vancomycin subsidized only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.

Source for notes 1-7: PHARMAC, Online Pharmaceutical Schedule. Available at:

https://schedule.pharmac.govt.nz/ScheduleOnline.php. Accessed on 03/06/2022.

Most antibiotic classes included in this study showed a significant decrease in utilisation ranging from 38.64% for sulphonamides to 80.64% for fluoroguinolones. However, cephalosporins showed a 4.76% increase in usage during the study period, and this was largely attributed to the increased utilisation of cephalexin and ceftriaxone. Although macrolide utilisation decreased significantly, the utilisation of azithromycin increased by just over 66 times that of 2005 by the end of 2019. Vancomycin only showed an overall increase of 13.8% in utilisation during the study period. In 2019, the top four single most utilised antibiotics were doxycycline (DDD/TOPD = 2.06), flucloxacillin (DDD/TOPD = 1.31), amoxicillin (DDD/TOPD = 1.28), and trimethoprim (DDD/TOPD = 1.12) (Table 1).

#### Utilisation by antibiotic classes

175

176 177

178

179

180

181 182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Except for aminoglycosides and fluoroguinolones, all included antibiotic classes showed a steady increase in utilisation until 2016 (Figure 1), followed by a sharp decline. Fluoroguinolone utilisation started declining in 2012, while aminoglycoside utilisation remained very low. The most utilised antibiotic classes were penicillins (DDD/TOPD = 3.78), tetracyclines (DDD/TOPD = 2.06), and macrolides (DDD/TOPD = 1.95) (Table 1). The biggest reduction in utilisation between 2005 and 2019 was on fluoroguinolones, which dropped by 80.7% (Table 1).

Utilisation by antibiotic class and age

- The total systemic antibiotic consumption increased with age but remained relatively 209
- steady from 2005 to 2017 (Figure 2). Penicillins were the most utilised antibiotics 210
- across all age groups. In addition, the DDD/TOPD for all classes, except 211
- aminoglycosides, increased with age. 212
- Utilisation by antibiotic class, age, and sex 213
- The rate of antibiotic consumption was constant in both males and females for all 214
- antibiotic classes (except fluoroguinolones) and age groups, except for the 95 years 215
- old and above males, whose consumption rate has been steadily increasing in all 216
- antibiotic classes (Figure 3). Between 65 and 79 years of age, antibiotic utilisation was 217
- similar for both sexes. Females had higher utilisation than males from age 80 to 94 218
- years. Among those 95 years and above, males had greater utilisation than females. 219
- Fluoroguinolone utilisation has been decreasing in all age groups for both males and 220
- females as early as 2012, except among the 95 years and above males, where the 221
- decrease in consumption started in about 2015. 222
- Interrupted time series analysis 223
- The observed data showed a slight upward trend and possible seasonality on analysis 224
- (Supporting file, Figures S1, S2 and S3). Before the intervention, the visible trend and 225
- seasonality determined stationarity by first difference (d = 1) and seasonal difference 226
- (D = 1). According to the undifferenced and differenced ACF/PACF plots obtained, the 227
- former showed autocorrelation at lag 12 (Supporting file, figure S4 and S5). After 228
- running the automated algorithm in R, the best model selected was (3,1,0) (0,1,1) [12]. 229
- Thus, autocorrelation order (p) was 3, the moving average order (g) was 0, the 230
- autocorrelation order for the seasonal part (P) was 0, and the moving average order 231
- for the seasonal part (Q) was 1. The p-value for the Ljung-Box test for white noise was 232
- 0.51 at 36 lags (Spporting file, figure S6); therefore, the chosen model had a good fit. 233
- Figure 4 is the final ARIMA model showing predicted values in the absence of an 234
- antimicrobial resistance action plan (counterfactual) compared to observed values. 235
- The estimated step change was minus 0.2206 (95% CI: -0.4619 0.0207) and the 236
- estimated change in slope was -0.0029 (95% CI: -0.0097 0.0039). 237

#### **Discussion**

238

239 240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

#### Overall trend

This study found that the overall utilisation of subsidised systemic antibiotics among older people in New Zealand dropped by 49.6% of the predicted utilisation rate for 2018/2019 following the implementation of the antimicrobial resistance action plan [24]. In a previous study, systemic antibiotic utilisation was reported to have increased 49% between 2006 and 2014 in New Zealand [15]. This increase is also reflected in this study, where utilisation of most antibiotic classes steadily increased until 2015 (Figure 1 and table 2). However, this was followed by a sharp decrease to more than 56% below the 2005 utilisation rate between 2018 and 2019.

We concluded that implementing the antimicrobial resistance action plan contributed significantly, but not exclusively, to the significant drop in total antibiotic utilisation rates in New Zealand in 2018 and 2019. In 2015, Thomas [25] called for immediate action to reduce antimicrobial prescribing in New Zealand, particularly in the community where most infections were self-limiting. His recommendations included not prescribing antibiotics where the infection was likely viral, not prescribing antibiotics for sore throat in all over eighteen (except for Māori and non-Pacific ethnicities), substituting amoxicillin-clavulanic acid with penicillin for Streptococcus pyogenes skin infections, and no fluoroquinolones for urinary tract infections. These recommendations were supported by the Antibiotic Consumption in New Zealand. 2006 - 2014 surveillance report [26]. Significant reduction in amoxicillin and amoxicillin-clavulanic acid utilisation rates would greatly impact total antibiotic utilisation since these two antibiotics contributed more than 42% of the total antibiotic utilisation rates for the period 2006 - 2014 [26]. The utilisation of these penicillins, and to a lesser extent macrolides and tetracyclines, followed a seasonal pattern with peaks during the winter months (June to August) and troughs during the summer months (December to February) in New Zealand [26]. The highest use of penicillins was reported among older adults of the Pacific Peoples, European (and other), Middle Eastern, Latin American, and African (MELAA) ethnicities. The utilisation of amoxicillin and amoxicillin-clavulanic acid doubled between 2006 and 2014, possibly overusing due to overlapping clinical features of indicated conditions with viral infections [26].

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

The antimicrobial resistance action plan was developed through a collaboration of various human, animal and agricultural stakeholders to respond to the ever-rising global challenge of antimicrobial resistance [24]. The implementation would be spread over five years from 2017, with the first year mainly for fact-finding, training, and resource mobilisation before rolling out the activities from year two onwards. One of the main objectives focussed on the optimisation of the use of antimicrobial medicines, whereby in 2017, the focus was on investigating inequalities in antimicrobial prescribing in community hospital settings and, from 2018, rolling out the appropriate activities to reduce antimicrobial consumption while promoting appropriate prescribing began [24]. In our study, we, therefore, considered January 2018 as the date of starting the measures recommended to reduce antimicrobial utilisation in New Zealand.

The ITS analysis, as shown in figure 4, has demonstrated that this intervention significantly impacted the antibiotic utilisation rate among older adults. The huge drop in total antibiotic utilisation rate was probably due to a huge drop in prescribing amoxicillin or amoxicillin-clavulanic acid following the implementation of the action plan. The Best Practice Advocacy Centre for New Zealand (BPACNZ) supported this and noted a sustained decrease in dispensed oral antibiotic prescriptions per 1000 registered patients [27]. In 2018 and 2019, there was an average of 3% to 5% annual drop in dispensed antibiotic prescriptions, according to the BPACNZ [27]. This decrease was attributed to New Zealand's improved antimicrobial stewardship. Our findings were further supported by Thomas et al.[28], who concluded that there was an overall decrease in dispensing of antibiotics among adults 60 years or above in New Zealand between 2015 and 2018. In their study, Thomas et al.[28] found that community antibiotic dispensing, measured as defined daily doses per 1,000 inhabitants per day, decreased by 4.6% per year during 2015-2018, with large reductions in dispensing of amoxicillin-clavulanate [28].

In a recent study, overall antibiotic utilisation was consistently higher in Australia compared to Sweden between 2006 and 2018 [14]. In Australia, the overall utilisation was steady, ranging from 21.8 DDD/TOPD in 2006 to 22.2 DDD/TOPD in 2018. whereas Sweden experienced a 26.2% decrease in utilisation between 2006 and 2018. Compared to Australia and Sweden, our results showed that New Zealand's drop in overall antibiotic utilisation was the fastest, which could have been

necessitated by the government's strong response to the increasing global challenge of antimicrobial resistance in 2016 [29].

The top four most utilised antibiotic agents in 2019 were doxycycline, flucloxacillin, amoxicillin, and trimethoprim (Table 1). This finding agrees with previous studies where doxycycline and amoxicillin consistently appeared on the top list of heavily consumed single antibiotics [14, 15]. However, in a separate US study, the top four most used antibiotics among older adults (65 years or more) were azithromycin, ciprofloxacin, amoxicillin, and cefalexin [30]. The differences in the usage of individual antibiotics are possibly due to different local and national antibiotic stewardship policies, treatment guidelines, subsidy arrangements, and non-adherence. [13, 31, 32].

### Utilisation by antibiotic class

303

304

305

306

307

308

309

310

311

312

313

314

- This study showed that in 2019 the most utilised antibiotic classes were penicillins, 315
- tetracyclines, and macrolides (Table 1). Previous studies have also found penicillins, 316
- extended-spectrum penicillins and beta-lactamase sensitive penicillins as the most 317
- heavily consumed antibiotic classes in New Zealand, Australia, and Sweden, 318
- respectively [14, 15]. This general agreement in utilisation trends, by class, of systemic 319
- antibiotics may indicate an internationally improved antibiotic stewardship. 320

#### Utilisation by age group and sex 321

- In this study, antibiotic utilisation rates generally varied with age and sex, increasing 322
- in the older age group (Figure 2). Williamson et al. [15] also found that antibiotic 323
- utilisation rates increased with age among the New Zealand population and were 324
- significantly and consistently higher in females than males between 2006 and 2014. 325
- Our study showed that antibiotic utilisation was similar for males and females between 326
- 65 and 79 years. However, females had a higher antibiotic utilisation rate than males 327
- between the ages of 80 and 94, and men of 95 years and above had a higher utilisation 328
- rate than women (Figure 3). Marquez et al.'s study support this finding that after age 329
- 65, men have higher innate and pro-inflammatory activity and lower adaptive activity 330
- than women [33]. 331

#### Limitations

One of the major limitations of dispensing data is the lack of information on antibiotics' indications and appropriateness. Therefore, adherence to antimicrobial therapy by the patients is not captured and accounted for when using such datasets. We used data for dispensing claims for funded antibiotics made by community pharmacies only, thus possibly missing data on unfunded antibiotics prescribed to the study population during the study period. Additionally, the Pharmaceutical Collections database does not include information about medicines dispensed in hospitals [34], so antibiotic exposure may have been underestimated if older adults received the drugs during hospitalisation. Our post-intervention observation period was relatively short (from January 2018 to December 2019) and therefore might not reflect the true impact of the intervention. Other factors besides the antimicrobial action plan may have played a significant role in the huge drop in antibiotic utilisation rates between 2018 and 2019. For example, there was already an annual 4.6% drop in antibiotic utilisation rate three years before the launch of the antimicrobial intervention plan [28].

### **Strengths**

The reimbursement system in New Zealand captures greater than 95% of the prescription coverage of older adults' census population, strengthening our study findings' validity. This study also acts as a proxy measure of adherence to national antibiotic prescribing policies and stewardship guidelines among older adults in New Zealand. In addition, the validity of our findings was strengthened by using the ARIMA models to perform the interrupted time series analysis to investigate the impact of the antimicrobial resistance action plan on antibiotic utilisation. Previous studies have demonstrated the utility and reliability of ARIMA models for evaluating population-level health interventions [18].

#### Conclusion

This study provides valuable information on the consumption of systemic antibiotics among the 65 years or above sub-population of New Zealand. It has also shown the effectiveness of the antimicrobial resistance action plan introduced by the government of New Zealand to mitigate antibiotic resistance by reducing inappropriate antimicrobial utilisation. The ITS analysis has demonstrated that this intervention hugely impacted the antibiotic utilisation rate among older adults. As a result, there was a significant reduction in the overall utilisation of systematic antibiotics between

367

368

369

370

371

372

373

374

375

376

377 378

379

380

381

382

383 384

385 386

387

388

389 390

391

392

393

394

2005 and 2019 among older adults in New Zealand. However, there were some age and sex differences in the consumption rates of antibiotics among the studied population. Further studies are required to determine whether the reduced consumption rates of antibiotics are associated with reduced rates of antibioticassociated adverse drug events such as acute kidney injury and haematological abnormalities. **Ethics statement:** The Departmental Research and Ethics Officer at the University of Bath assessed the ethical implications of research activity (EIRA) and approved this study on behalf of the University of Bath's Research, Integrity, and Ethics committee. Approval number EIRA 1-4048. Acknowledgement The authors thank the Analytical Services, Ministry of Health of New Zealand, for supplying the data extracted from the Pharms database. **Author contributions** TC (Bath) serves as the first author of the manuscript. He led all the stages of the development of this manuscript while PN supervised. TC (Otago), TC (Bath), and PN contributed to statistical analysis, interpretation of results, and manuscript revision. SR and HJ also contributed to interpreting the results and manuscript revision. All authors approved the final manuscript. Conflict of interest: The authors have no conflicts of interest to declare Funding: No funding was received **Data availability:** The data is owned by the Analytical Services, Ministry of Health,

New Zealand, so supporting data is not available

#### References

- Pulia MS, Keller SC, Crnich CJ, Jump RLP, Yoshikawa TT. Antibiotic 398 1.
- Stewardship for Older Adults in Ambulatory Care Settings: Addressing an Unmet 399
- Challenge. J Am Geriatr Soc. 2020;68(2):244-9. 400
- 2. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse 401
- Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 402
- 2017;177(9):1308-15. 403
- Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, et al. 3. 404
- Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in 405
- Hospitalized Patients: A Single-center Study. Intern Med. 2019;58(18):2621-5. 406
- 407 King LM, Bartoces M, Fleming-Dutra KE, Roberts RM, Hicks LA. Changes in
- US Outpatient Antibiotic Prescriptions From 2011-2016. Clin Infect Dis. 408
- 2020;70(3):370-7. 409
- 5. Kabbani S, Palms D, Bartoces M, Stone N, Hicks LA. Outpatient Antibiotic 410
- Prescribing for Older Adults in the United States: 2011 to 2014. J Am Geriatr Soc. 411
- 2018;66(10):1998-2002. 412
- 413 6. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, Jr.,
- et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory 414
- 415 Care Visits, 2010-2011. Jama. 2016;315(17):1864-73.
- 7. Silverman M, Povitz M, Sontrop JM, Li L, Richard L, Cejic S, et al. Antibiotic 416
- Prescribing for Nonbacterial Acute Upper Respiratory Infections in Elderly Persons. 417
- Ann Intern Med. 2017;166(11):765-74. 418
- 8. Schmidt ML, Spencer MD, Davidson LE. Patient, Provider, and Practice 419
- Characteristics Associated with Inappropriate Antimicrobial Prescribing in 420
- Ambulatory Practices. Infect Control Hosp Epidemiol. 2018;39(3):307-15. 421
- 9. Tanner LA, Baum C. Spontaneous adverse reaction reporting in the elderly. 422
- Lancet. 1988;2(8610):580. 423
- Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits 10. 424
- for antibiotic-associated adverse events. Clin Infect Dis. 2008;47(6):735-43. 425
- 426 11. Sakoulas G. Adverse effects of fluoroguinolones: where do we stand now.
- NEJM Journal Watch. 2019;13. 427

- 12. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, et al. 428
- Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and 429
- death. Ann Fam Med. 2014;12(2):121-7. 430
- 13. Robertson J, Vlahović-Palčevski V, Iwamoto K, Högberg LD, Godman B, 431
- Monnet DL, et al. Variations in the Consumption of Antimicrobial Medicines in the 432
- European Region, 2014-2018: Findings and Implications from ESAC-Net and WHO 433
- Europe. Front Pharmacol. 2021;12:639207. 434
- Andersson K, van Driel M, Hedin K, Hollingworth S, Merlo G. Antibiotic use in 14. 435
- 436 Australian and Swedish primary care: a cross-country comparison. Scand J Prim
- Health Care. 2022:1-9. 437
- Williamson DA, Roos R, Verrall A, Smith A, Thomas MG. Trends, 15. 438
- demographics and disparities in outpatient antibiotic consumption in New Zealand: a 439
- national study. J Antimicrob Chemother. 2016;71(12):3593-8. 440
- 16. Tomlin AM, Woods DJ, Reid JJ, Tilyard MW. Trends in prescription medicine 441
- use by older people in New Zealand 2010- 2015: a national population-based study. 442
- N Z Med J. 2020;133(1513):61-72. 443
- 17. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for 444
- 445 the evaluation of public health interventions: a tutorial. Int J Epidemiol.
- 2017;46(1):348-55. 446
- 18. Schaffer AL, Dobbins TA, Pearson SA. Interrupted time series analysis using 447
- autoregressive integrated moving average (ARIMA) models: a guide for evaluating 448
- large-scale health interventions. BMC Med Res Methodol. 2021;21(1):58. 449
- Ministry of Health. Pharmaceutical collection. Publicly funded pharmaceutical 19. 450
- dispensings between 1 January 2005 and 31 December 2016. . 2017. 451
- collection. MoHP. Publicly funded pharmaceutical dispensings between 1 July 452
- 2012 and 31 December 2019 for a selected cohort. 2020. 453
- Narayan SW, Hilmer SN, Horsburgh S, Nishtala PS. Anticholinergic 454
- component of the Drug Burden Index and the Anticholinergic Drug Scale as 455
- measures of anticholinergic exposure in older people in New Zealand: a population-456
- level study. Drugs Aging. 2013;30(11):927-34. 457
- Who Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 22. 458
- 2022 [cited 2022 31/05/2022]. Available from: 459
- https://www.whocc.no/atc ddd index/. 460

- 23. R Core Team. R: A language and environment for statistical computing.: R 461
- Foundation for Statistical Computing, Vienna, Austria.; 2022 [updated April 2022; 462
- cited 2022 05/05/2022]. R-4.2.0:[Available from: https://www.R-project.org/. 463
- 24. Ministry of Health and Ministry for Primary Industries. New Zealand 464
- Antimicrobial Resistance Action Plan. In: Industries. MoHaMfP, editor. Wellington: 465
- Ministry of Health; 2017. 466
- 25. Thomas M. Upfront: Time to reduce antibiotic prescribing – NOW. Best 467
- Practice Journal New Zealand. 2015(68). 468
- 469 Williamson DA, Roos, R.F., Verrall, A. Antibiotic Consumption in New
- Zealand, 2006-2014. In: Zealand. TloESaRLPN, editor. Porirua2016. 470
- Best Practice Advocacy Centre New Zealand. National Report: Overview of 471
- national dispensing during 2020 2021 [cited 2022 21/10/2022]. Available from: 472
- https://bpac.org.nz/report/2020/national-dispensing.aspx#dispensing. 473
- 28. Thomas M, Tomlin A, Duffy E, Tilyard M. Reduced community antibiotic 474
- dispensing in New Zealand during 2015-2018: marked variation in relation to primary 475
- health organisation. N Z Med J. 2020;133(1518):33-42. 476
- 29. Ministry of Health and Ministry for Primary Industries. Antimicrobial 477
- 478 Resistance: New Zealand's current situation and identified areas for action. In:
- Industries MoHaMfP, editor. Wellington: Ministry of Health; 2017. 479
- 30. Olesen SW, Barnett ML, MacFadden DR, Lipsitch M, Grad YH. Trends in 480
- outpatient antibiotic use and prescribing practice among US older adults, 2011-15: 481
- observational study. Bmj. 2018;362:k3155. 482
- Auta A, Hadi MA, Oga E, Adewuyi EO, Abdu-Aguye SN, Adeloye D, et al. 31. 483
- Global access to antibiotics without prescription in community pharmacies: A 484
- systematic review and meta-analysis. J Infect. 2019;78(1):8-18. 485
- 32. Browne AJ, Chipeta MG, Haines-Woodhouse G, Kumaran EPA, Hamadani 486
- BHK, Zaraa S, et al. Global antibiotic consumption and usage in humans, 2000-18: a 487
- spatial modelling study. Lancet Planet Health. 2021;5(12):e893-e904. 488
- Márquez EJ, Chung CH, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, et 33. 489
- al. Sexual-dimorphism in human immune system aging. Nat Commun. 490
- 2020;11(1):751. 491
- Donald S, Sharples K, Barson D, Horsburgh S, Parkin L. Patterns of 34. 492
- prescription medicine dispensing before and during pregnancy in New Zealand, 493
- 2005-2015. PLoS One. 2020;15(6):e0234153. 494




Figure 1: Systemic antibacterial utilisation by antibiotic class, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand.

# Figure 1




Figure 2: Systemic antibacterial class consumption by age group, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand




Figure 3: Systemic antibacterial class consumption by age group and sex, expressed as defined daily doses per thousand older people per day (DDD/TOPD), from 2005 to 2019 for older adults (65 years or more) in New Zealand.

## Interrupted time series analysis: Final ARIMA model




Figure 4: Final ARIMA model showing predicted values in the absence of antimicrobial resistance action plan (counterfactual) compared to observed values.

Step = -0.2206 (95% CI: -0.4619 - 0.0207).

Ramp = -0.0029 (95% CI: -0.0097 - 0.0039)

Key:

Counterfactual = Red. Observed values = Blue. Intervention date = Grey dotted vertical